Objective: Primary malignant brain tumors are relatively uncommon, and their incidence and survival rates have seldom been reported.
Introduction
Brain tumors are a mixed group of primary and metastatic neoplasms that exhibit varying degrees of malignancy. Malignant lesions are relatively uncommon, but their incidence has increased rapidly in highly developed, industrialized countries [1] . Primary malignant brain tumors have drawn wide attention not only because of their poor prognosis, but also for their direct impact on neurologic function, psychological health, and quality of life [2] . Over the past decades, advances in diagnostic methods have revealed a trend toward an increased incidence of brain tumors [3, 4] . The introduction of computed tomography in the mid-1970s and magnetic resonance imaging in the mid-1980s improved the detection of these lesions [4] . However, recent large-scale cohort-and population-based studies have produced mixed results regarding incidence trends. Some studies have found a level-off or even a slight decrease [1, 5, 6] , while others have found the opposite [7] . These previous studies focused on primary brain-or central nervous system tumors; little is known about the trends in incidence of primary versus metastatic malignant brain tumors. The only well-established reported risk factors are ionizing radiation and rare hereditary syndromes such as neurofibromatosis [4] . The relation between primary malignant brain tumors and the usage of cell phones is still a topic of debate [8] . Understanding the epidemiology is required to facilitate early detection, treatment, and prevention of malignant brain tumors.
Cancer Incidence in Five Continents (CI5) Volume IX and X presents incidence data from populations all over the world from 1998 to 2002 [9] and from 2003 to 2007 [10] . This volume covers 11% and 14% of the worldwide population respectively. However, Taiwan is not included in this volume. Therefore, the purpose of our study is to estimate the trends in incidence over time of primary malignant brain tumors according to sex and age, using the National Health Insurance (NHI) Database, which contains health information for the entire population of Taiwan.
Materials and methods
This study was approved by the Institutional Review Board of Chang Gung Memorial Hospital (approval number 201602029B0). As we used anonymized data, patient consent was exempted. A research grant from the Chang Gung Memorial Hospital supported this study.
Source of data and study population
The primary data source was the NHI database. The Taiwanese NHI was established in 1995 as a single-payer system requiring all residents to enroll. In 2012, the coverage rate was exceptional, at 99.5%. The Administration of National Health Insurance routinely collected registration-and original claims data generated by the NHI and released the information as a single database after anonymization of personal details. The database contains comprehensive information regarding beneficiaries' personal information, diagnoses, medications, procedures, family relationships, vaccines, operations, and fees incurred. Multiple diagnoses recorded in NHI have been validated [9] [10] [11] [12] , and the recordings in the database are generally considered accurate.
Patients with primary malignant brain tumors were referred to and treated by specialists. They were entitled to a waiver for medical copayment, granted after a formal review of the relevant clinical and pathological evidence by a commissioned expert committee. In this study, we identified patients with brain tumors using the registry of catastrophic illnesses, which records all patients who received such benefits.
Definition of malignant brain tumor
The primary definition of malignant brain tumor used for this study was a physician-recorded primary diagnosis of malignant brain tumor (International Classification of Diseases, Ninth Revision [ICD-9] code:191) recorded in the catastrophic illness registry. We obtained data from all patients in the NHI database with a primary malignant brain tumor between 1997 and 2012. To ascertain the validity of brain cancer diagnoses in the NHI database, we compared the diagnoses of primary malignant brain tumor in the NHI with the National Cancer Registry. Agreement between the 2 databases was good, with a sensitivity of 0.86 and a specificity of 1.
Estimation of prevalence and incidence
Incident patients were those who had no evidence of disease prior to the first of January of each calendar year but who developed a malignant brain tumor during that year. To be eligible, beneficiaries had to have at least 1 year of registration in the database prior to the first of January of each calendar year. We constructed at-risk cohorts that included all individuals registered during a given calendar year who had no history of a malignant brain tumor diagnosis before the first of January of that year. The incidence was calculated using the number of patients with incident primary malignant brain tumors during a calendar year as the numerator, and the total person-years at-risk population of that same year as the denominator.
Standardized incidence of malignant brain tumor
To determine trends in the incidence of primary malignant brain tumor, we calculated age-and sex-standardized incidence using the population structure in Taiwan in 2012 as the reference. 
Mortality and causes of death
Survival status and causes of death between 1997 and 2012 were ascertained using the National Death Registry in Taiwan, which records the deaths of all citizens, coding the causes of death from death certificates. The accuracy of the coding has been validated by previous studies [13] . We estimated 1-year survival rates for calendar years 1997-2012, 2-year survival rates for 1997-2011, and 5-year survival rates for 1997-2008.
Statistical analysis
The 95% confidence interval (CI) for incidence was derived based on the assumption of a Poisson distribution for the observed number of incident patients. We used the Joinpoint Regression Program (version 4.0.4) to estimate trends in the incidence and survival rates of malignant brain tumors. The program used the Bayesian information criterion to generate different numbers of "joinpoints" that partition the linear trend into periods with statistically different slopes using the best-fit data series [14] . A maximum of 2 joinpoints were used to determine statistical significance for the trend. Annual percentage changes (APCs) for each segment were calculated. The secular trends for incidence and survival were calculated for patients with a Charlson comorbidity score of 0-2 and ≥ 3. The Charlson comorbidity index (CCI) was used to evaluate patients' burden of comorbidities and to estimate the risk of death from 17 diagnostic conditions (weighted score 1: myocardial infarction, congestive heart disease, peripheral vascular disease, cerebrovascular disease, dementia, chronic pulmonary disease, connective tissue disease, peptic ulcer disease, mild liver disease, diabetes without complications; score 2: diabetes with complications, hemiplegia and paraplegia, renal disease, any malignancy including leukemia and lymphoma without metastasis; score 3: moderate or severe liver disease; score 6: malignant metastasis and acquired immune deficiency syndrome). The significance level was set at 0.05. All statistical analyses were performed using SAS statistical software, version 9.3.
Results
We identified 7746 male and 5846 female patients with primary malignant brain tumors in Taiwan between 1997 and 2012. The mean age at diagnosis was 49 years. Patient characteristics are shown in Table 1 .
Incidence of primary malignant brain tumor between 1997 and 2012
Fig . 1 shows the temporal trends in the standardized incidence of malignant brain tumors between 1997 and 2012. The APC of the standardized incidence was 0.1 (95% CI, −1.9 to 2.2). This was not statistically significant, suggesting that the overall incidence of primary malignant brain tumor was essentially the same throughout the study period, taking into account age and sex (Tables 2 and 3 
Incidence of primary malignant brain tumor in 2012
There were a total 21,582,604 person-years of follow-up for 2012. A total of 825 incident cases of primary malignant brain tumor were identified, with an overall incidence of 3.82 per 100,000 person-years [95% CI, 3.56-4.08]. The incidence was 4.44 [95% CI, 4.04-4.84] in men and 3.22 [95% CI, 2.88-3.56] in women. Overall, the incidence was higher in the adult group, at 4.2 per 100,000 person-years [95% CI, 3.89-4.5]. In the pediatric group, the incidence was 2.35 [95% CI, 1.9-2.8] per 100,000 person-years (Table 3 ). Men had a higher incidence than women at all ages (Fig. 2) . The incidence of primary malignant brain tumor in both men and women was low in those younger than 40 years of age, but thereafter increased rapidly until the age of 70 years.
Survival rates of primary malignant brain tumors between 1997 and 2012
Of the 13592 patients with primary malignant brain tumors diagnosed between 1997 and 2012, the overall 1-, 2-, and 5-year survival was 65.7% (95% CI, 62.1-69.0), 43.4% (95% CI, 39.9-46.8), and 28.1% (95% CI, 24.9-31.3). Overall, the 1-year survival rate was 53.8% (95% CI, 50.0-57.5) in 1997 and 67.6% (64.3%-70.7%) in 2012 ( Table 4 ). The APC was 1.1 (0.7-1.5) for this period, suggesting an improvement in short-term mortality; and the average APC of 2-year survival between 1997 and 2011 was 0.9 (0.3-1.6). However, the average APC of 5-year survival was 0.2 (−1.0 to 1.4), suggesting that long-term survival did not improve (Fig. 3) . Similar trends were observed in overall survival in male and female groups, those with a (Fig. 4) .
Geographic distribution of primary malignant brain tumors in Taiwan
Fig . 5 shows the geographic distribution of incidence in Taiwan in 2012. The higher incidence areas were Miaoli, Tainan, and Hualien counties. For patients below 20 years of age, Hsinchu county, Taichung city, and Taitung county were high-incidence areas. For patients above 20 years of age, Miaoli, Hualien, and Nantou counties were highincidence areas.
Discussion
Cancer is the leading cause of death worldwide, with 8.2 million people dying each year. In Taiwan, cancer was also the leading cause of death in 2014 and 2015 (http://iiqsw.mohw.gov.tw/st3/index.html). Although the incidence of primary malignant brain tumors is relatively low compared with other cancers, the former usually cause severe neurologic dysfunction and influence quality of life. The trends of incidence and survival for primary malignant brain tumors, using the data of the Taiwanese NHI, give us a chance to understand the changes in incidence and survival in this area of Asia.
Changes in incidence of primary malignant brain tumor
The worldwide annual age-standardized incidence of primary malignant brain tumors is 3.7 per 100,000 for men and 2.6 per 100,000 for women [8, 10] . Rates appear to be higher in more developed countries (men, 5.8 per 100,000; women, 4.1 per 100,000) than in less developed countries (men, 3.0 per 100,000; women, 2.1 per 100,000) [12] . In the United States, the annual age-adjusted incidence of primary malignant brain tumor from 2008 to 2012 was 7.44, 7.35, 7.21, 7.12, and 7.02 per 100,000 [1] . In comparison, the annual ageadjusted incidence (age-adjusted to the United States standard population in 2000) In Taiwan from 2008 to 2012 was 4.06, 3.91, 4.34, 4.05, and 3.85 per 100,000. A relatively low incidence in Taiwan was found, considering that it is a developed country. One may expect an increased incidence due to early detection, as with other cancers, with improvements in global public health. However, there are few reports describing trends in the incidence of primary malignant brain tumors in Taiwan from 1997 to 2012.
Inconsistent with the existing literature comparing the incidence of primary brain tumors between the United States and Taiwan from 2002 to 2010 using the databases of the Unites States and Taiwan Cancer Registry [15] , we found that primary malignant brain tumors seem to be slowly decreasing from 1999 to 2012; this is compatible with findings in the United States [1] , where the incidence of primary malignant brain tumors gradually decreased between 2008 and 2012. Differences in databases (i.e., National Health Insurance versus Cancer Registry) or the codes use (i.e., ICD-9 CM versus International Classification for Disease, Oncology, third edition) might be reasons for the discrepancy in results between this study and the previous report [15] . Of note, the findings from joinpoint analysis suggested that the incidence decreased between 1999 and 2012, with an APC of −1.8 [95% CI, −2.5 to −1.0]. Several factors, including screening practices, disparities in lifestyle, environmental exposure, and health policy, might explain this matter [15] . However, this study could not ascertain the association due to the limitation of study design.
In the pediatric group, primary malignant brain tumors are the most common cancer among those aged 0-19 years, ranging from 2.27 to 4.81 per 100,000 population, with an average annual age-adjusted incidence of 5.57 per 100,000 in the United States [1] . In Kuwait, the overall incidence between 1995 and 2011 was 1.12 per 100,000 population. In Japan, the overall incidence of primary malignant brain tumor in ages 0-14 years is 3.61 per 100,000; in Denmark, Finland, Norway, and Sweden, the incidence is 4.20 per 100,000 persons [16] . Our data indicate that the incidence of primary malignant brain tumor ranges from 1.70 to 2.35 per 100,000 between 1998 and 2012. There is no increasing or decreasing trend in the pediatric age group. This is a relatively low incidence compared with developed countries (e.g., United states, Japan, Northern Europe) [16] .
The incidence of all brain-and central nervous system tumors is highest in the group aged 85 years and over (83.14 per 100,000) and lowest among children and adolescents aged 0-19 years (5.57 per 100,000) in the United States [1] , where approximately 55.0% occur in males and 45% in females [13] . In Taiwan, a relatively low incidence was noted in patients aged less than 20 years, while an increased incidence was found in those aged over 40 years. The highest incidence is in those aged over 80 years. Men have higher rates of primary malignant brain tumors, especially those older than 40 years of age. The incidence in Taiwan and the United States is comparable.
Cancer Incidence in Five Continents (CI5) Volume IX and X shows regional variations in the incidence of malignant brain tumors (agestandardized incidence adjusted to Segi-Doll world population), with a higher incidence seen in Western, developed countries. Asian countries tend to display lower incidence. In Japan, the age-standardized incidence in males is 2.1-3.5 per 100,000 and in females is 1.5-2.5 per 100,000. In Korea, the male age-standardized incidence is 2.5-3.6 and in females is 2.1-3.2. In Singapore, the male age-standardized incidence is 2.0-3.2 and in females is 1.2-2.4 [9, 10] . In our Taiwanese data, age-standardized incidence (age-adjusted to Segi-Doll world population) showed 4.94-6.09 in male and 3.56-4.78 in female from 1998 to 2007. We observed a relatively high age-standardized incidence relative to other Asian countries. However, males have a higher incidence of primary malignant brain tumor in most countries, including Taiwan.
Improvement in survival
Overall survival rate of primary malignant brain tumor in Taiwan from another publication showed 1-year, 2-year, and 5-year survival rate are 68.1%, 49.9%, and 34.3% [15] . These data are similar to ours, but higher than that in Unites States. The reasons may be larger proportion of glioblastoma multiforme and lower insurance coverage rate [15] .
Primary malignant brain tumors are the most common solid tumor and the second leading cause of cancer-related death in individuals This means that medical progress in Taiwan improved the short-term survival of pediatric brain tumors in patients with comorbidities, but there was no effect on long-term survival.
In adults, we observed a significant increase in overall, male, and female 1-year and 2-year survival. However, the 5-year survival in these same groups did not improve significantly. In other words, short-term survival improved, but long-term survival did not. In the United States, the 5-and 10-year survival rates for primary malignant brain tumors are 29.1% and 25.3% according to data from the American Cancer Society website (www.cancer.org accessed on March 1, 2008) [12] . These findings are compatible with our data. Survival times are increasing due to innovations in diagnosis and therapy [11] . For example, chemotherapy using temozolomide with concurrent radiotherapy has become a standard treatment for glioblastoma, which accounts for 54% of primary malignant brain tumors since 2005 in the United States [11] and in Taiwan. This may be among the reasons for the improved short-term survival seen over recent years.
Comorbidities influences survival
Several investigators have attempted to determine whether there is a relation between comorbidity and cancer prognosis. Comorbidities may modify the treatment of older cancer patients. Numerous reports, notably epidemiologic studies, have observed that comorbidities affect both treatment and prognosis, making it difficult to separate the respective contributions of the comorbidity, functional status, and treatment reduction to the prognosis [17] . Research also shows that preexisting diabetes mellitus and an elevated body mass index are independent risk factors for poor outcome in patients with high-grade glioma [19, 20] . The CCI takes 17 conditions into consideration and predicts 10-year mortality. The CCI significantly impacts patient outcomes and may be employed for preoperative patient risk stratification [18] .
We noted that overall survival improved for both 1-year and 2-year data. Taking comorbidities into consideration, the improvement in the group with a CCI < 3 is only seen in 1-year survival for both the overall group and the adult group, but not the pediatric group. Improvement in 2-year survival was noted in the adult group but not in the pediatric group. Several studies have reported that comorbidities may worsen the prognosis; therefore, if comorbid disease is under better control, the prognosis will be better. This may be the cause of the improved survival seen in the group with a CCI > 3 between 1998 and 2012. We may be the first to report that controlling comorbidities could improve short-term survival for all primary malignant brain tumors, not just glioblastomas. Our data indicate that controlling comorbidities has an impact on survival in malignant brain tumors, especially in adults. They also imply that further improvement in long-term survival may require more effective anticancer treatment.
Association between geographic variations in malignant brain tumor
Our findings suggested that some areas yielded higher incidence rates of primary malignant brain tumor than other counties. Note that these counties were not all high population density areas, indicating no substantial association between population density and the incidence of primary malignant brain tumors. Several risk factors have been recognized to be associated with primary malignant brain tumors, such as chemical exposure, radiation exposure, and certain genetic syndromes [15, 21] . However, we could not determine the mechanism underlying this association. Therefore, the nature of the relationship between must be further explored.
Limitations
This is a retrospective study based on the NHI database. We were not able to differentiate between various types of intracranial pathology. Different pathology may occur in different age groups and sexes and may receive variable treatment, therefore contributing a different percentage of improvement for survival.
Conclusions
A slightly decreased trend in incidence of primary malignant brain tumors was observed in Taiwanese general population since 1999. Over the past 15 years, we have seen improvement in the short-term survival of primary malignant brain tumors, especially in adults. Chen Wei; Study supervision: Chang-Fu Kuo.
Author contributions

